![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novartis Ag Basel Namen Akt (PK) | USOTC:NVSEF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 105.17 | 104.29 | 118.12 | 20 | 21:20:00 |
Form 20-F: x
|
Form 40-F: o
|
Yes: o
|
No: x
|
Yes: o
|
No: x
|
Yes: o
|
No: x
|
![]() |
Novartis International AG
Novartis Global Communications
CH-4002 Basel
Switzerland
http://www.novartis.com
|
MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG |
|
·
|
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months
|
|
·
|
Filing is based on results from the landmark PARADIGM-HF study1
|
|
·
|
Nearly six million people live with heart failure in the US, and despite current therapies, up to 50% of patients die within five years of diagnosis2,3
|
1.
|
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
|
2.
|
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics – 2015 Update: A Report from the American Heart Association. Circulation. 2015;131:00-00.
|
3.
|
Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344-350.
|
4.
|
U.S. Food and Drug Administration. Priority Review. http://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm. Updated September 15, 2014. Accessed January 27, 2015.
|
5.
|
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240-e327.
|
6.
|
Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discovery Today: Therapeutic Strategies. 2012;9(4):e131-e139. doi: 10.1016/j.ddstr.2013.11.002.
|
7.
|
Fauci A, Longo D. Disorders of the Heart. Harrison’s ‘Principles of Internal Medicine. 17th ed. 2008;4:1442-55.
|
8.
|
Cook C, Cole G, Asaria P et al, The annual global economic burden of heart failure. Int J Cardiol. 2014.;171(3):368-76
|
9.
|
Neumann T, Biermann J, Erbel R et al, Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int. 2009;106:269–75.
|
10.
|
Stewart S, Jenkins A, Buchan S et al, The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002 Jun;4(3):36-71.
|
Central media line : +41 61 324 2200
|
|
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
|
Julie Masow
Novartis Global Media Relations]
+41 61 324 8137 (direct)
+1 862 579 8456 (mobile)
julie.masow@novartis.com
|
Central phone:
|
+41 61 324 7944
|
||
Samir Shah
|
+41 61 324 7944
|
North America:
|
|
Pierre-Michel Bringer
|
+41 61 324 1065
|
Richard Pulik
|
+1 212 830 2448
|
Thomas Hungerbuehler
|
+41 61 324 8425
|
Susan Donofrio
|
+1 862 778 9257
|
Isabella Zinck
|
+41 61 324 7188
|
||
e-mail: investor.relations@novartis.com
|
e-mail: investor.relations@novartis.com
|
Novartis AG
|
|||
Date: February 13, 2015
|
By:
|
/s/ MALCOLM B. CHEETHAM
|
|
Name:
|
Malcolm B. Cheetham
|
||
Title:
|
Head Group Financial Reporting and Accounting
|
||
1 Year Novartis Ag Basel Namen ... (PK) Chart |
1 Month Novartis Ag Basel Namen ... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions